U.S. stock futures slip lower; Cook’s firing increases Fed independence worries
CRANBURY, N.J. - Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company with a market capitalization of $4.29 million, has initiated an appeal against the NYSE American’s decision to delist its common stock, the company announced today. The appeal follows a determination by NYSE Regulation that Palatin failed to meet the stockholders’ equity requirements by the April 10, 2025 deadline, concluding an 18-month period allocated for compliance. According to InvestingPro data, the company’s stock has declined 85% year-to-date, currently trading near its 52-week low of $0.17.
During the appeal process, which is expected to last between 60 to 90 days, Palatin’s common stock will remain actively traded on the NYSE American. The outcome of the appeal, to be decided by the NYSE Listings Qualifications Panel, will ultimately determine whether the company’s stock will continue to be listed or will be delisted. InvestingPro analysis reveals concerning financial health metrics, with a weak overall score of 1.67 out of 5, suggesting significant challenges ahead. For deeper insights into Palatin’s financial position and future prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
Palatin is actively pursuing several strategies to strengthen its financial position and meet the listing criteria, particularly crucial given its current ratio of 0.38, indicating potential liquidity challenges. These strategies include accelerating licensing discussions for its development programs, advancing equity financing negotiations, and exploring other strategic funding opportunities. Carl Spana, Ph.D., President and CEO of Palatin, expressed the company’s commitment to addressing the listing requirements swiftly and effectively, aiming to restore compliance and establish a more robust foundation for future growth.
The company’s optimism about meeting the listing requirements and its dedication to shareholder value is tempered by the acknowledgment that there is no certainty of success in the appeal process. This announcement contains forward-looking statements regarding the company’s expectations of regaining compliance, which are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from historical or anticipated results. For comprehensive analysis and real-time updates on Palatin’s financial situation, visit InvestingPro, where subscribers can access detailed financial metrics, expert insights, and exclusive ProTips.
The information in this article is based on a press release statement from Palatin Technologies, Inc.
In other recent news, Palatin Technologies, Inc. has been notified by NYSE American LLC of a potential delisting due to non-compliance with stockholders’ equity requirements. The company plans to appeal this decision, and trading is expected to continue during the appeal process. In clinical developments, Palatin reported significant improvements in patients with Type 2 diabetic nephropathy using their melanocortin agonist treatment, with 71% of participants showing reduced kidney damage. Additionally, a Phase 2 obesity study demonstrated significant weight loss with a drug combination, achieving a 4.4% average reduction in weight. The company also announced promising results from its Phase 2 trial of PL8177 for ulcerative colitis, with 33% of patients achieving clinical remission. Furthermore, Palatin’s investigational oral treatment, PL7737, received orphan drug designation from the FDA for LEPR deficiency obesity, providing incentives such as tax credits and potential market exclusivity. These recent developments highlight Palatin Technologies’ ongoing efforts in advancing treatments for various medical conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.